-
About Hayfin
About Hayfin
Since our formation in 2009, Hayfin has grown to become Europe’s leading alternative asset management platform. We have developed in a measured way to build transatlantic capabilities and establish a growing local presence in Asia.
-
Strategies
Strategies
We provide critical debt, equity and hybrid capital solutions tailored to the European market. Our product suite is designed to address every financing need of non-investment grade borrowers, providing broad and flexible mandates. Covering both primary and secondary markets and providing financing across the spectrum from growth to stress or distress.
-
People
People
Led by Hayfin’s Executive Committee, our international team of industry professionals represent the best experience and expertise in the market. Our people embrace our values and culture contributing to our collective success.
-
Responsibility
- News & Views
- Contact
- Home
- News & Views
- Hayfin co-leads Impilo’s €320m single-asset Continuation Fund for Immedica Pharma
News 25th October 2024
Hayfin co-leads Impilo’s €320m single-asset Continuation Fund for Immedica Pharma
Hayfin is pleased to announce that it is serving as the co-lead investor through its Private Equity Solutions strategy, alongside funds managed by Morgan Stanley Private Equity Secondaries, in a €320 million Single-Asset Continuation Fund established by Impilo to support its continued ownership of Immedica.
Headquartered in Stockholm, Sweden, Immedica is a pharmaceutical company focused on the commericalization of specialty medicines for rare and orphan diseases. Serving patients in more than 50 countries, Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Established in 2018 by Impilo and an experienced management team, Immedica has quickly emerged as a leader in the European rare disease space, with revenues of c. EUR 100m and annual growth of more than 50%.
This Continuation Fund transaction follows the recently announced completion of Impilo’s partial sale of Immedica to KKR, who together with Impilo will jointly oversee Immedica through this next phase of growth.
Mirja Lehmler-Brown, Managing Director and Co-Head of Private Equity Solutions at Hayfin commented: “We are excited to continue our partnership with Impilo in supporting Immedica during this pivotal time for the business. The Continuation Fund will aim to support the company with funding for its continued growth journey, furthering its mission to deliver essential therapies to patients with significant unmet medical needs.”